Literature DB >> 10832496

Content versus label claims in ephedra-containing dietary supplements.

B J Gurley1, S F Gardner, M A Hubbard.   

Abstract

The content of ephedra alkaloids in herbal dietary supplements containing ephedra (ma huang) was studied. The ephedra alkaloid content of 20 ephedra-containing supplements was determined by high-performance liquid chromatography. Contents of (-)-ephedrine, (+)-pseudoephedrine, (-)-methylephedrine, (-)-norephedrine, and (+)-norpseudoephedrine were measured. Ephedra alkaloid content varied considerably among products. Total alkaloid content ranged from 0.0 to 18.5 mg per dosage unit. Ranges for (-)-ephedrine and (+)-pseudoephedrine were 1.1-15.3 mg and 0.2-9.5 mg, respectively. (+)-Norpseudoephedrine, a Schedule IV controlled substance, was often present. Significant lot-to-lot variations in alkaloid content were observed for four products. For one product, lot-to-lot variations in the content of (-)-ephedrine, (+)-pseudoephedrine, and (-)-methylephedrine exceeded 180%, 250%, and 1000%, respectively. Half of the products exhibited discrepancies between the label claim for ephedra alkaloid content and actual alkaloid content in excess of 20%. One product was devoid of ephedra alkaloids. Assay of 20 ephedra-containing dietary supplements showed that alkaloid content often differed markedly from label claims and was inconsistent between two lots of some products.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10832496     DOI: 10.1093/ajhp/57.10.963

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  15 in total

1.  Selected physical and chemical properties of commercial Hypericum perforatum extracts relevant for formulated product quality and performance.

Authors:  S H Kopleman; A NguyenPho; W S Zito; F X Muller; L L Augsburger
Journal:  AAPS PharmSci       Date:  2001

Review 2.  Addressing the potential risks associated with ephedra use: a review of recent efforts.

Authors:  Sara Schulman
Journal:  Public Health Rep       Date:  2003 Nov-Dec       Impact factor: 2.792

3.  Coronary thrombosis related to use of Xenadrine RFA.

Authors:  Rajesh Sachdeva; Satish Sivasankaran; Robert F Fishman; Stuart W Zarich; Craig A McPherson
Journal:  Tex Heart Inst J       Date:  2005

Review 4.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Pharmacokinetic Drug Interactions with Panax ginseng.

Authors:  Meenakshi R Ramanathan; Scott R Penzak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

6.  Complementary and alternative medicine use by otolaryngology patients: a paradigm for practitioners in all surgical specialties.

Authors:  Muhammad Shakeel; Aaron Trinidade; Kim W Ah-See
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-09-22       Impact factor: 2.503

7.  Dietary supplements and herbal medicine toxicities-when to anticipate them and how to manage them.

Authors:  D H Phua; A Zosel; K Heard
Journal:  Int J Emerg Med       Date:  2009-06-10

Review 8.  The natural treatment of hypertension.

Authors:  Amanda James Wilburn; Deborah S King; James Glisson; Robin W Rockhold; Marion R Wofford
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-05       Impact factor: 3.738

Review 9.  Cytochrome P450 enzyme mediated herbal drug interactions (Part 2).

Authors:  Sompon Wanwimolruk; Kamonrat Phopin; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2014-08-20       Impact factor: 4.068

Review 10.  Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States.

Authors:  Mark I Avigan; Robert P Mozersky; Leonard B Seeff
Journal:  Int J Mol Sci       Date:  2016-03-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.